CoChat

Epicardial injection of allogeneic human-induced-pluripotent stem cell-derived cardiomyocytes in patients with advanced heart failure: protocol for a phase I/IIa dose-escalation clinical trial

Open access

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Heart failure (HF) is a growing global public health burden. However, due to the very limited regenerative capacity of mature cardiomyocytes in the adult mammalian heart, conventional treatments can only improve the symptoms of HF but fail to restore cardiac function. Heart transplantation is limited by a severe shortage of donors. Cell-based transplantation for the treatment of HF has become a promising strategy. Human-induced-pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) have been tested in animal models to assess safety and efficacy. This study aims at evaluating the safety and efficacy of epicardial injection of hiPSC-CMs in patients with advanced HF during coronary artery bypass grafting (CABG) surgery. METHODS: cells, sequentially). Patients with advanced heart failure will be enrolled and randomly allocated to receive epicardial injection of hiPSC-CMs during CABG surgery or CABG surgery alone, followed by a 12-month follow-up investigation. The primary endpoint is to assess the safety of hiPSC-CMs transplantation, including haemodynamic compromised sustained ventricular arrhythmias and newly formed tumours during 6 months postoperatively. The secondary endpoint is to evaluate the efficacy of epicardial injection of hiPSC-CMs and CABG surgery combination by comparison with CABG surgery alone. ETHICS AND DISSEMINATION: The study protocol has been approved by the Institutional Ethical Committee of Nanjing Drum Tower Hospital (No. SC202000102) and approved by National Health Commission of the PRC (MR-32-21-014649). Findings will be disseminated to the academic community through peer-reviewed publications and presentation at national and international meetings. TRIAL REGISTRATION NUMBER: NCT03763136.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmjopen-2021-056264

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The modified 3+3 dose-escalation study design. CABG, coronary artery bypass graft; MTD, maximum tolerated dose; SAE, serious adverse event, grade 4 or above cell implant-related adverse event.
Figure 1 The modified 3+3 dose-escalation study design. CABG, coronary artery bypass graft; MTD, maximum tolerated dose; SAE, serious adverse event, grade 4 or above cell implant-related adverse event.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 46

Metadata

Authors
Zhang, H., Xue, Y., Pan, T., Zhu, X., Chong, H., Xu, C., Fan, F., Cao, H., Zhang, B., Pan, J., Zhou, Q., Yang, G., Wang, J., & Wang, D.-J.
Affiliations
  • Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
  • Nanjing Drum Tower Hospital (CN)
  • Department of Cardiothoracic Surgery, Nanjing University Medical School Affiliated Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
  • HELP Therapeutics (China) (CN)
Corresponding author
Wang, Jiaxian
Venue
BMJ Open
Publisher
BMJ
Published
2022-05
Volume
12
Issue
5
Pages
e056264
ISSN
2044-6055 (ISSN-L)
OpenAlex
W4229069980
Cited by
44
References
27
Citations by year
2026: 9 · 2025: 12 · 2024: 11 · 2023: 9 · 2022: 3
FWCI
2.86
Type
journal article
Language
en
Open access
Locations
  • BMJ Open (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (acceptedVersion)
Funders
Help Therapeutics (NA)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
  • Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
Keywords
advanced heart failure, human induced pluripotent stem cell-derived cardiomyocytes, coronary artery bypass grafting, allogeneic cell transplantation, cell transplantation safety, ventricular arrhythmias, tumor formation
MeSH terms
Coronary Artery Bypass, Heart Failure, Humans, Randomized Controlled Trials as Topic, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Hematopoietic Stem Cell Transplantation, Myocytes, Cardiac, Induced Pluripotent Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Epicardial injection of allogeneic human-induced-pluripotent stem cell-derived cardiomyocytes in patients with advanced heart failure: protocol for a phase I/IIa dose-escalation clinical trial. https://app.cochat.ai/papers/10.1136/bmjopen-2021-056264
The paper
Zhang, H., Xue, Y., Pan, T., Zhu, X., Chong, H., Xu, C., Fan, F., Cao, H., Zhang, B., Pan, J., Zhou, Q., Yang, G., Wang, J., & Wang, D.-J. (2022). Epicardial injection of allogeneic human-induced-pluripotent stem cell-derived cardiomyocytes in patients with advanced heart failure: protocol for a phase I/IIa dose-escalation clinical trial. BMJ Open. https://doi.org/10.1136/bmjopen-2021-056264

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.